New York, USA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Psoriatic Arthritis Market to Register Immense Growth by 2032, Assesses DelveInsight | Key Companies to Look Out - Bristol-Myers Squibb, Aclaris, AbbVie, Novartis, Janssen, MoonLake, Affibody, Amgen, Eli Lilly
The psoriatic arthritis market is anticipated to grow positively in the coming years in 7MM owing to the subsequent launch of biosimilars and biologics, as well as the rise in prevalence and expedite R&D.
DelveInsight’s Psoriatic Arthritis Market Insights report includes a comprehensive understanding of current treatment practices, psoriatic arthritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Psoriatic Arthritis Market Report
- As per DelveInsight’s analysis, the psoriatic arthritis market size was found to be ~USD 9 billion in 2021 and it is anticipated to grow at a significant CAGR by 2032.
- As per the DelveInsight estimates, in 2021, the total prevalent cases of psoriatic arthritis in the 7MM were more than 1.4 million, of which the highest cases were observed in the United States.
- Leading psoriatic arthritis companies such as ACELYRIN Inc., Sun Pharmaceutical Industries Limited, UCB Pharma, Ventyx Biosciences, Inc, Bristol-Myers Squibb, Aclaris Therapeutics, Inc., AbbVie, Novartis, Janssen Research & Development, LLC, MoonLake Immunotherapeutics AG, Affibody AB, Amgen, Eli Lilly and Company, PRA Health Sciences, and others are developing novel psoriatic arthritis drugs that can be available in the psoriatic arthritis market in the coming years.
- Some of the key therapies for psoriatic arthritis treatment include Izokibep, SUNPG18_07, Bimekizumab, VTX958, Deucravacitinib, ATI-450, Risankizumab, Upadacitinib, AIN457, Ustekinumab, Sonelokimab, and others.
Discover which therapies are expected to grab the major psoriatic arthritis market share @ Psoriatic Arthritis Market Report
Psoriatic Arthritis Overview
Psoriatic arthritis is a chronic autoimmune condition that primarily affects individuals with psoriasis, a skin disorder characterized by red, scaly patches on the skin’s surface. This condition causes inflammation in the joints, leading to pain, stiffness, and swelling. It is considered a systemic disease because it can also affect other parts of the body beyond the joints. The exact cause of psoriatic arthritis is not fully understood, but it is believed to result from a combination of genetic predisposition and environmental factors.
Psoriatic arthritis symptoms can vary widely and may include joint pain, swelling, and stiffness, often accompanied by skin symptoms of psoriasis. The joints most commonly affected are those of the fingers and toes, but larger joints like the knees, ankles, and spine can also be involved. Additionally, some individuals may experience fatigue, nail changes, and eye inflammation. A comprehensive medical history, physical examination, and assessment of skin and nail changes are crucial components of psoriatic arthritis diagnosis. Medical imaging, such as X-rays and MRI scans, may reveal characteristic joint changes associated with the condition. Blood tests may be conducted to rule out other forms of arthritis and to check for markers of inflammation.
Psoriatic Arthritis Epidemiology Segmentation
The psoriatic arthritis epidemiology section provides insights into the historical and current psoriatic arthritis patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The psoriatic arthritis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Psoriatic Arthritis Prevalent Cases
- Total Psoriatic Arthritis Diagnosed Cases
- Psoriatic Arthritis Gender-specific Cases
- Psoriatic Arthritis Age-specific Cases
- Psoriatic Arthritis Severity-specific Cases
Download the report to understand which factors are driving psoriatic arthritis epidemiology trends @ Psoriatic Arthritis Epidemiological Insights
Psoriatic Arthritis Treatment Market
In recent years, the landscape of psoriatic arthritis treatment has witnessed remarkable advancements, offering patients a more comprehensive and personalized approach to managing this complex condition. Beyond the traditional arsenal of NSAIDs and DMARDs, the emergence of biological therapies has been a game-changer. Biologics, designed to target specific immune pathways and proteins, have demonstrated remarkable efficacy in controlling both joint inflammation and skin manifestations of psoriatic arthritis. These innovative medications not only alleviate symptoms but also potentially halt disease progression, preventing long-term joint damage and disability.
However, the treatment journey extends beyond pharmaceutical interventions. Multidisciplinary care involving rheumatologists, dermatologists, and physical therapists ensures a holistic approach. Physical therapy and exercise regimens are tailored to individual capabilities, aiming to maintain joint flexibility, muscle strength, and overall function. Moreover, the recognition of the gut-skin axis and the role of diet in inflammatory conditions has prompted research into the impact of certain foods and dietary habits on psoriatic arthritis. This has led to increased awareness of the potential benefits of anti-inflammatory diets rich in antioxidants and omega-3 fatty acids.
Furthermore, the advent of digital health tools and wearable devices has empowered patients to actively monitor their condition, track symptoms, and engage in telemedicine consultations. These technological advances not only enhance communication between patients and healthcare providers but also enable early intervention and prompt adjustments to treatment plans, fostering a proactive and patient-centered approach.
To know more about psoriatic arthritis treatment, visit @ Psoriatic Arthritis Treatment Drugs
Key Psoriatic Arthritis Therapies and Companies
- Izokibep: ACELYRIN Inc.
- SUNPG18_07: Sun Pharmaceutical Industries Limited
- Bimekizumab: UCB Pharma
- VTX958: Ventyx Biosciences, Inc
- Deucravacitinib: Bristol-Myers Squibb
- ATI-450: Aclaris Therapeutics, Inc.
- Risankizumab: AbbVie
- Upadacitinib: AbbVie
- AIN457: Novartis
- Ustekinumab: Janssen Research & Development, LLC
- Sonelokimab: MoonLake Immunotherapeutics AG
Learn more about the FDA-approved drugs for psoriatic arthritis @ Drugs for Psoriatic Arthritis Treatment
Psoriatic Arthritis Market Dynamics
The psoriatic arthritis market dynamics reflect a complex interplay of factors that influence its diagnosis, treatment, and overall management. With the growing recognition of PsA as a distinct and potentially debilitating condition, the psoriatic arthritis market has witnessed an increased focus on research and development of innovative therapies. Advancements in diagnostic techniques, including imaging and biomarker-based approaches, have enhanced early detection and monitoring. The evolving treatment landscape is characterized by a range of options, such as disease-modifying antirheumatic drugs (DMARDs), biologics, and targeted therapies, each catering to different patient profiles.
The competitive nature of the psoriatic arthritis market has driven efforts to improve patient outcomes, minimize joint damage, and alleviate symptoms. Moreover, patient-centric initiatives and a greater emphasis on personalized medicine are reshaping the psoriatic arthritis market, fostering a holistic approach to care. As the understanding of PsA deepens and therapeutic options expand, the psoriatic arthritis market dynamics continue to shift, shaping a future where patients can experience improved quality of life and better disease control.
However, several factors are impeding the growth of the psoriatic arthritis market. Limited public awareness and a lack of comprehensive screening programs often result in delayed diagnoses, hampering timely intervention. Additionally, the high cost of innovative therapies, including biologics and targeted treatments, poses a significant barrier to accessibility for many patients. Regulatory hurdles and the need for extensive clinical trials further contribute to the time and resources required for new treatments to enter the psoriatic arthritis market.
Moreover, the variability in patient responses to existing therapies underscores the necessity for more personalized approaches, necessitating the development of biomarkers and precision medicine strategies. Overcoming these barriers requires collaborative efforts from healthcare providers, pharmaceutical companies, regulatory bodies, and patient advocacy groups to ensure equitable access, accelerate research, and optimize treatment outcomes for individuals battling PsA.
| Psoriatic Arthritis Report Metrics | Details |
| Study Period | 2019–2032 |
| Psoriatic Arthritis Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Psoriatic Arthritis Market Size in 2021 | USD 9 Billion |
| Key Psoriatic Arthritis Companies | ACELYRIN Inc., Sun Pharmaceutical Industries Limited, UCB Pharma, Ventyx Biosciences, Inc, Bristol-Myers Squibb, Aclaris Therapeutics, Inc., AbbVie, Novartis, Janssen Research & Development, LLC, MoonLake Immunotherapeutics AG, Affibody AB, Amgen, Eli Lilly and Company, PRA Health Sciences, and others |
| Key Psoriatic Arthritis Therapies | Izokibep, SUNPG18_07, Bimekizumab, VTX958, Deucravacitinib, ATI-450, Risankizumab, Upadacitinib, AIN457, Ustekinumab, Sonelokimab, and others |
Scope of the Psoriatic Arthritis Market Report
- Therapeutic Assessment: Psoriatic Arthritis current marketed and emerging therapies
- Psoriatic Arthritis Market Dynamics: Attribute Analysis of Emerging Psoriatic Arthritis Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Psoriatic Arthritis Market Access and Reimbursement
Discover more about psoriatic arthritis drugs in development @ Psoriatic Arthritis Clinical Trials
Table of Contents
| 1. | Psoriatic Arthritis Market Key Insights |
| 2. | Psoriatic Arthritis Market Report Introduction |
| 3. | Psoriatic Arthritis Market Overview at a Glance |
| 4. | Psoriatic Arthritis Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Psoriatic Arthritis Treatment and Management |
| 7. | Psoriatic Arthritis Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Psoriatic Arthritis Marketed Drugs |
| 10. | Psoriatic Arthritis Emerging Drugs |
| 11. | Seven Major Psoriatic Arthritis Market Analysis |
| 12. | Psoriatic Arthritis Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | Appendix |
| 18. | DelveInsight Capabilities |
| 19. | Disclaimer |
| 20. | About DelveInsight |
Related Reports
Psoriatic Arthritis Epidemiology Forecast
Psoriatic Arthritis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted psoriatic arthritis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Psoriatic Arthritis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key psoriatic arthritis companies including Sun Pharmaceutical Industries Limited, UCB Biopharma, Bristol-Myers Squibb, AbGenomics, Boehringer Ingelheim, Affibody, AltruBio, Bio-Thera Solutions, Dong-A ST, 3SBio, Qyuns Therapeutics, Kangpu Biopharmaceuticals, Alpine Immune Sciences, Polpharma Biologics, Avotres, XBiotech, Aclaris Therapeutics, Luye Pharma Group, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Nimbus Therapeutics, f5 Therapeutics, MoonLake Immunotherapeutics, among others.
Psoriasis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key psoriasis companies, including Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals, among others.
Psoriasis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psoriasis companies, including Hangzhou Highlightll Pharmaceutical Co., Ltd, Biohaven Pharmaceuticals, Inc., SFA Therapeutics, Bristol-Myers Squibb, Ventyx Biosciences, Inc, Amgen, AbbVie, Alumis Inc, DICE Therapeutics, Inc., UCB Pharma, Janssen Research & Development, LLC, Arcutis Biotherapeutics, Inc., AnaptysBio, Inc., Sun Pharmaceutical Industries Limited, Novartis, Pfizer, Boehringer Ingelheim, KoBioLabs, Abcentra, Aclaris Therapeutics, among others.
Psoriasis Epidemiology Forecast
Psoriasis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted psoriasis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Other Trending Reports
Digestive System Fistula Market | Dementia With Diabetes Market | Leber's Hereditary Optic Neuropathy Market | Pecoma Market | Adamantinoma Market | Pegfilgrastim Biosimilar Insight | Functional Constipation Market | DDR Defective Tumors Market | Nephrotic Syndrome Pipeline | Pelizaeus-Merzbacher Disease Market | Hepatic Impairment Market | Primary Ciliary Dyskinesia Market | Surgical Bleeding Market | Radiotherapy-Induced Oral Mucositis Market | Relapsed Chronic Lymphocytic Leukemia CLL Market | Galactosemia Market | Glabellar Lines Market | Homozygous Familial Hypercholesterolemia Market | HR Positive/ HER2 Negative Breast Cancer Market | Lebers Hereditary Optic Neuropathy LHON Market | Nonalcoholic Fatty Liver Disease NAFLD Market | Orthotic Devices Market | Polypoidal Choroidal Vasculopathy Market | Sporadic Inclusion Body Myositis Market | Warm Autoimmune Hemolytic Anemia Market | Acid Sphingomyelinase Deficiency ASMD Market | B-Cell Chronic Lymphocytic Leukemia Market | Coccidioidomycosis Market | Frontotemporal Dementia Pipeline | Granulomatosis With Polyangiitis Market | Malignant Pleural Mesothelioma Market | Nocturnal Enuresis Market | Postmyocardial Infarction Syndrome Market | Severe Acute Respiratory Syndrome Sars Coronavirus Infection Market | Typhoid Fever Market | Ventricular Dysfunction Market | Burkitt Lymphoma Market | Chronic Progressive Multiple Sclerosis Market | Emesis Market | Fenebrutinib Market | Gastric Neuroendocrine Tumors Market | Juvenile Rheumatoid Arthritis Market | Persistent Epithelial Defects Market | Post-Polycythemia Vera Myelofibrosis Market | Primary Mediastinal Large B-Cell Lymphoma Market | Spinocerebellar Ataxias Market | Systemic Inflammatory Response Syndrome Market | Triple Negative Breast Cancer Market | Visceral Pain Associated With GI Disorders Market | Adrenal Cortex Neoplasms Market | Adrenal Insufficiency Market | Artificial Lung Devices Market | Atopic Keratoconjunctivitis AKC Market | Autonomic Dysfunction Market | Bradycardia Treatment Devices Market | Bullous Pemphigoid Market | Cone Rod Dystrophy Market | Cutaneous Lupus Erythematosus Market | Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market | Dermal Regeneration Matrix Market | Heart Pump Devices Market | Hemiplegia Market | Hepatic Impairement Market | Immunologic Deficiency Syndrome Market | Implantable Infusion Pump Market | Menorrhalgia Market Size | Myocarditis Market | Myopia Treatment Devices Market | Ocular Hypertension Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
